Elevation Oncology Inc (NAS:ELEV)
$ 3.84 0.15 (4.07%) Market Cap: 209.81 Mil Enterprise Value: 136.57 Mil PE Ratio: 0 PB Ratio: 2.62 GF Score: 21/100

Elevation Oncology Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 15, 2023 / 12:00PM GMT
Release Date Price: $2.32 (+62.24%)
Alexander Xu
Oppenheimer & Co. Inc. - Analyst

Great. Good morning, everyone. Welcome to Oppenheimer's 33rd Healthcare Conference. Joining me today is Elevation Oncology's Interim CEO and Chief Financial Officer, Joseph Ferra. Just a quick overview, Elevation is a biotech company currently transitioning to development of EO-3021, an anti-Claudin 18.2 ADC.

You may remember that they previously were working on an anti-HER3 NRG1 fusion asset, which they brought to Phase 2 development, and they're currently seeking another partner for developing this asset. If it's okay with you, I'd like to hand it over to you, Joseph.

Joseph Ferra
Elevation Oncology, Inc. - Interim CEO & CFO

Sure. Great. Thank you very much, Alex, and thank you to the entire Oppenheimer team for hosting us today. Good morning, everyone. As Alex said, I'm Joseph Ferra, Interim Chief Executive Officer and CFO of Elevation Oncology. I look forward to telling you more about our company today and our highlight of making it -- highlight out of our focus on making a difference for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot